Van Thanh Hoang

Van Thanh Hoang

Auto-generated profile, based on publicly available information

Van Thanh Hoang

Vinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, Vin University, Hanoi, Vietnam

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in Medcomm
Verified
Journal Article
Open access
VHVan T. Hoang
Van T. Hoang
QNQuyen Thi Nguyen
Quyen Thi Nguyen
TPTrang Thi Kieu Phan
Trang Thi Kieu Phan
TPTrang H. Pham
Trang H. Pham
NDNhung Thi Hong Dinh
Nhung Thi Hong Dinh
LTLiem Nguyen Thanh
Liem Nguyen Thanh
From the pioneering days of cell therapy to the achievement of bioprinting organs, tissue engineering, and regenerative medicine have seen tremendous technological advancements, offering solutions for restoring damaged tissues and organs. However, only a few products and technologies have received United States Food and Drug Administration approval. This review highlights significant progress in cell therapy, extracellular vesicle‐based therapy, and tissue engineering. Hematopoietic stem cell transplantation is a powerful tool for treating many diseases, especially hematological malignancies. Mesenchymal stem cells have been extensively studied. The discovery of induced pluripotent stem cells has revolutionized disease modeling and regenerative applications, paving the way for personalized medicine. Gene therapy represents an innovative approach to the treatment of genetic disorders. Additionally, extracellular vesicle‐based therapies have emerged as rising stars, offering promising solutions in diagnostics, cell‐free therapeutics, drug delivery, and targeted therapy. Advances in tissue engineering enable complex tissue constructs, further transforming the field. Despite these advancements, many technical, ethical, and regulatory challenges remain. This review addresses the current bottlenecks, emphasizing novel technologies and interdisciplinary research to overcome these hurdles. Standardizing practices and conducting clinical trials will balance innovation and regulation, improving patient outcomes and quality of life.

1 January 2021 in Cytotherapy
Verified
Journal Article
Closed access
VHVan T. Hoang
Van T. Hoang
QTQuynh-Mai Trinh
Quynh-Mai Trinh
DPDam Thi Minh Phuong
Dam Thi Minh Phuong
HBHue Thi Hong Bui
Hue Thi Hong Bui
LHLe Minh Hang
Le Minh Hang
DHDuc M. Hoang
Duc M. Hoang

27 February 2024 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
VHVan T. Hoang
Van T. Hoang
DLDuc Son Le
Duc Son Le
DHDuc M. Hoang
Duc M. Hoang
TPTrang Thi Kieu Phan
Trang Thi Kieu Phan
LNLan Anh Thi Ngo
Lan Anh Thi Ngo
LTLiem Nguyen Thanh
Liem Nguyen Thanh
Background: Hyperactive coagulation might cause dangerous complications such as portal vein thrombosis and pulmonary embolism after mesenchymal stem/stromal cell (MSC) therapy. Tissue factor (TF), an initiator of the extrinsic coagulation pathway, has been suggested as a predictor of this process. Methods: The expression of TF and other pro- and anticoagulant genes was analyzed in xeno- and serum-free manufactured MSCs. Furthermore, culture factors affecting its expression in MSCs were investigated. Finally, coagulation tests of fibrinogen, D-dimer, aPPTs, PTs, and TTs were measured in patient serum after umbilical cord (UC)-MSC infusions to challenge a potential connection between TF expression and MSC-induced coagulant activity. Results: Xeno- and serum-free cultured adipose tissue and UC-derived MSCs expressed the highest level of TF, followed by those from dental pulp, and the lowest expression was observed in MSCs of bone marrow origin. Environmental factors such as cell density, hypoxia, and inflammation impact TF expression, so in vitro analysis might fail to reflect their in vivo behaviors. MSCs also expressed heterogeneous levels of the coagulant factor COL1A1 and surface phosphatidylserine and anticoagulant factors TFPI and PTGIR. MSCs of diverse origins induced fibrin clots in healthy plasma that were partially suppressed by an anti-TF inhibitory monoclonal antibody. Furthermore, human umbilical vein endothelial cells exhibited coagulant activity in vitro despite their negative expression of TF and COL1A1. Patients receiving intravenous UC-MSC infusion exhibited a transient increase in D-dimer serum concentration, while this remained stable in the group with intrathecal infusion. There was no correlation between TF expression and D-dimer or other coagulation indicators. Conclusions: The study suggests that TF cannot be used as a solid biomarker to predict MSC-induced hypercoagulation. Local administration, prophylactic intervention with anticoagulation drugs, and monitoring of coagulation indicators are useful to prevent thrombogenic events in patients receiving MSCs. Trial registration NCT05292625. Registered March 23, 2022, retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT05292625?term=NCT05292625&draw=2&rank=1. NCT04919135. Registered June 9, 2021, https://www.clinicaltrials.gov/ct2/show/NCT04919135?term=NCT04919135&draw=2&rank=1.

25 June 2023 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
QNQuyen Thi Nguyen
Quyen Thi Nguyen
LTLiem Nguyen Thanh
Liem Nguyen Thanh
VHVan T. Hoang
Van T. Hoang
TPTrang T. K. Phan
Trang T. K. Phan
MHMichael Heke
Michael Heke
DHDuc M. Hoang
Duc M. Hoang

16 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QNQuyen Thi Nguyen
Quyen Thi Nguyen
NDNhung Thi Hong Dinh
Nhung Thi Hong Dinh
NHNgo Thu Hang
Ngo Thu Hang
CMCan Van Mao
Can Van Mao
XDXuan-Hai Do
Xuan-Hai Do
LTLiem Nguyen Thanh
Liem Nguyen Thanh
Extracellular vesicles (EVs) hold great promise as regenerative therapeutics due to their roles in intercellular communication and tissue repair. This study aimed to assess the safety of EVs derived from human mesenchymal stem cells (MSCs) obtained from both umbilical cord (UC-MSC-EVs) and adipose tissue (AD-MSC-EVs) sources, which were manufactured under xeno- and serum-free conditions and primed with 5% O2. EVs from neither source caused vascular or muscular stimulation in New Zealand rabbits. Systemic hypersensitivity tests revealed that neither UC-MSC-EVs nor AD-MSC-EVs triggered significant changes in allergic and immune responses or hematological parameters in the animals, highlighting their biocompatibility and safety when administered systemically. Furthermore, acute toxicity test using Swiss mice showed all mice survived without any signs of acute toxicity after intravenous injection of both types of EVs at very high doses (up to 10,000 µg/kg of body weight). In addition, subchronic toxicity examination in Wistar rats revealed that repeated injections of neither UC-MSC-EVs nor AD-MSC-EVs (50–150 µg/animal) affected hematological indices or the functions of the liver, kidney, or spleen. Collectively, our findings provide strong evidence that both UC-MSC-EVs and AD-MSC-EVs manufactured under xeno- and serum-free conditions and primed with 5% O2 are safe for potential therapeutic use. These results contribute to the growing body of evidence supporting the safety of physoxic MSC-derived EVs as therapeutic drugs, confirming their potential for applications in regenerative medicine.

24 November 2025 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
LNLiem Thanh Nguyen
Liem Thanh Nguyen
TNThuy Thi Ngoc Nguyen
Thuy Thi Ngoc Nguyen
KNKien Trung Nguyen
Kien Trung Nguyen
LPLam Nam Phung
Lam Nam Phung
VHVan Thanh Hoang
Van Thanh Hoang
CNChi Van Nguyen
Chi Van Nguyen
Background: Stroke is a leading cause of death worldwide. Traditional treatments have limitations, stem cell therapy has potential for regeneration after ischemic stroke. This study evaluated the safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell (UC-MSC) infusion via the intravenous (IV) and intrathecal (IT) routes for treating neurological sequelae after ischemic stroke. Methods: This phase II randomized controlled trial involved 32 patients aged 40–75 years with neurological sequelae after ischemic stroke. The patients were randomly assigned into two groups: 16 received two IT UC-MSC infusions plus rehabilitation therapy, and 16 received two IV UC-MSC infusions plus rehabilitation therapy. Additionally, 16 matched controls, paired with the IT group by sex, age (±5 years), and NIHSS, received only rehabilitation. UC-MSCs were administered at 1.5 × 106 cells/kg at baseline and 3 months. Outcomes were assessed at baseline, 3, 6, and 12 months using NIHSS, FIM, MAS, FMS, and SF-36. Results: No severe adverse events related to UC-MSC therapy were observed. Adverse event rate was lower in the IV group than the IT group. At 6 months, the IV group demonstrated significant improvements in NIHSS (p = 0.046), FIM (p = 0.028), and SF-36 (p < 0.001). At 12 months, both UC-MSC groups showed significant improvements, with greater effects in the IV group (p < 0.001 for SF-36). Conclusion: Both IV and IT UC-MSC infusions improved neurological recovery and quality of life, with fewer adverse events in the IT group. Trial registration: NCT05292625